Patents by Inventor Andrew Goodearl

Andrew Goodearl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140212423
    Abstract: Engineered multivalent and multispecific binding proteins capable of penetrating the blood-brain barrier (BBB) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: December 4, 2013
    Publication date: July 31, 2014
    Applicant: ABBVIE, INC.
    Inventors: Denise KARAOGLU HANZATIAN, Tariq GHAYUR, Annette J. SCHWARTZ STERMAN, Andrew GOODEARL, Maria Cristina HARRIS
  • Patent number: 7541338
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: June 2, 2009
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Publication number: 20080234190
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Application
    Filed: July 30, 2007
    Publication date: September 25, 2008
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Publication number: 20070281306
    Abstract: The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 21, 2006
    Publication date: December 6, 2007
    Inventors: Martin Hodge, Clare Lloyd, Nadine Weich, Jose Lora, David White, Maria Glucksmann, Keith Robison, Inmaculada Silos-Santiago, Andrew Goodearl, Rory Curtis
  • Patent number: 7285531
    Abstract: The invention involves prophylaxis or treatment of nervous system pathological conditions. This is accomplished by administering secretable glial growth factors, such as the molecule referred to as GGF-2.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 23, 2007
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Patent number: 7192915
    Abstract: Disclosed is the characterization and purification of DNA encoding polypeptides useful for the stimulation of glial cell mitogenesis. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides in the prevention or treatment of multiple sclerosis.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: March 20, 2007
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Publication number: 20070048771
    Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Application
    Filed: July 21, 2006
    Publication date: March 1, 2007
    Inventors: Sean McCarthy, Christopher Fraser, John Sharp, Thomas Barnes, Susan Kirst, Paul Myers, Nicholas Wrighton, Andrew Goodearl, Douglas Holtzman, Mehran Khodadoust
  • Patent number: 7135456
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells. The present invention is specifically directed to methods of using said polypeptides to induce myelination and to treat multiple sclerosis.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 14, 2006
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Publication number: 20060211848
    Abstract: The invention relates to Tango-73, Tango-74, Tango-76, Tango-78, and Tango-83 polypeptides, nucleic acid molecules encoding Tango-73, Tango-74, Tango-76, Tango-78, and Tango-83, and uses thereof. The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided.
    Type: Application
    Filed: May 26, 2006
    Publication date: September 21, 2006
    Inventors: Douglas Holtzman, Andrew Goodearl, Sean McCarthy
  • Patent number: 7094749
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: August 22, 2006
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Patent number: 6972280
    Abstract: Disclosed are methods for inducing myelination of neural cells by glial cells, The methods involve contacting glial cells with polypeptides comprising epidermal growth factor-like domains encoded by the GGF/p185 erb B2 ligand gene provided as a feature of the invention.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: December 6, 2005
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Publication number: 20050172345
    Abstract: The invention provides isolated nucleic acids molecules, designated muscarinic acetylcholine receptor 6 (“mACHR-6”) nucleic acid molecules, which encode polypeptides involved in the modulation of acetylcholine responses in acetylcholine responsive cells. The invention also provides antisense nucleic acid molecules, expression vectors containing mACHR-6 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an mACHR-6 gene has been introduced or disrupted. The invention still further provides isolated mACHR-6 polypeptides, fusion polypeptides, antigenic peptides, and anti-mACHR-6 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 15, 2005
    Publication date: August 4, 2005
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Andrew Goodearl, M. Glucksmann
  • Publication number: 20050106666
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Application
    Filed: May 12, 2004
    Publication date: May 19, 2005
    Applicants: Cambridge NeuroScience, Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Chen, Ian Hiles
  • Publication number: 20050019810
    Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Application
    Filed: July 28, 2004
    Publication date: January 27, 2005
    Inventors: Douglas Holtzman, Andrew Goodearl, Sean McCarthy
  • Publication number: 20030207799
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Application
    Filed: October 22, 1996
    Publication date: November 6, 2003
    Inventors: ANDREW GOODEARL, PAUL STROOBANT, LUISA MINGHETTI, MICHAEL WATERFIELD, MARK MARCHIONI, MARIO SU CHEN, IAN HILES
  • Patent number: 6232286
    Abstract: The invention features methods for stimulating glial cell mitogenesis by contacting the glial cells with p185erbB2 ligand polypeptides, including glial growth factor (GGF), a GGF splice variant comprised of segments E, B, A, C, and C/D or C/D′, a 35 kD polypeptide factor isolated from rat I-EJ transformed fibroblast cells, 75 kD polypeptide factor isolated from the LKBR-3 human breast cells, 44 kD polypeptide factor isolated from the rat I-EJ transformed fibroblast cells, 45 kD polypeptide factor isolated from MDA-MB 231 human breast cells, 7-14 kD polypeptide factor isolated from the ATL-2 human T-cells, 25 kD polypeptide factor isolated from activated mouse peritoneal macrophages, and 25 kD polypeptide factor isolated from bovine kidney.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 15, 2001
    Assignees: Cambridge Neuroscience, Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Patent number: 6194377
    Abstract: Disclosed are methods for treating pathophysiological conditions of the mammalian nervous system. The methods involve administering pharmaceutically effective amounts of recombinant polypeptides comprising epidermal growth factor-like domains encoded by the GGF/p185erbB2 ligand gene.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: February 27, 2001
    Assignees: Cambridge NeuroScience, Inc., The Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Patent number: 6147190
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 14, 2000
    Assignees: Cambridge NeuroScience, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Patent number: 5854220
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: December 29, 1998
    Assignees: Cambridge NeuroScience, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Patent number: 5792849
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 11, 1998
    Assignees: Ludwig Institute for Cancer Research and Cambridge NeuroScience, Cambridge NeuroScience
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles